SRD5A2 and benign prostatic hyperplasia: In vivo, SIN treatment reduced protein expression of SRD5A2 significantly in the PG tissue of mice with TP-induced BPH (Figure 4B), and SIN tended to decrease DHT in serum (Figure 4A), a finding that was consistent with data in the in vivo study.